Molecular Partners AG (SWX: MOLN)
Switzerland
· Delayed Price · Currency is CHF
4.430
+0.370 (9.11%)
Jan 3, 2025, 5:31 PM CET
Molecular Partners AG Revenue
Molecular Partners AG had revenue of 681.00K CHF in the quarter ending September 30, 2024, a decrease of -73.20%. This brings the company's revenue in the last twelve months to 6.00M, down -31.03% year-over-year. In the year 2023, Molecular Partners AG had annual revenue of 7.04M, down -96.29%.
Revenue (ttm)
6.00M
Revenue Growth
-31.03%
P/S Ratio
24.38
Revenue / Employee
35.73K
Employees
168
Market Cap
163.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 60.58B |
Novartis AG | 42.18B |
Lonza Group AG | 6.70B |
Alcon | 8.25B |
Galderma Group AG | 3.88B |
Straumann Holding AG | 2.54B |
Sonova Holding AG | 3.71B |
Sandoz Group AG | 9.09B |
Molecular Partners AG News
- 18 days ago - Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January - GlobeNewsWire
- 27 days ago - Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 - GlobeNewsWire
- 2 months ago - Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 - GlobeNewsWire
- 2 months ago - Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going - GlobeNewsWire
- 2 months ago - Molecular Partners prices $20M offering - Seeking Alpha
- 2 months ago - Molecular Partners Announces Pricing of $20 Million Underwritten Offering - GlobeNewsWire
- 2 months ago - Molecular Partners stock climbs 6% on expanded radiopharmaceuticals deal - Seeking Alpha
- 2 months ago - Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 - GlobeNewsWire